HF
PCVX icon

HRT Financial’s Vaxcyte PCVX Stock Holding History

HRT Financial’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.1M Buy
+53,300
New +$2.89M 0.01% 1296

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HRT Financial's PCVX Position: Q1 2026 in Review

HRT Financial reduced its Vaxcyte (PCVX) stake by 67% in Q1 2026, selling an estimated $4.16M and leaving 37,318 shares worth $2.17M. The position accounts for 0.01% of the portfolio, ranked #1569.

HRT Financial first reported a position in PCVX in Q1 2023 and has held it in 4 quarters since. The position peaked at $5.26M in Q4 2025. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • HRT Financial held 37,318 shares of Vaxcyte worth $2.17M as of Q1 2026.
  • HRT Financial sold 76,632 Vaxcyte shares in Q1 2026, an estimated $4.16M.
  • Vaxcyte made up 0.01% of HRT Financial's portfolio in Q1 2026, its #1569 holding.
  • HRT Financial first reported a position in Vaxcyte in Q1 2023 and has held it in 4 quarters since.
  • HRT Financial's Vaxcyte position peaked at $5.26M in Q4 2025.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.